Trial Profile
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms OASIS-1
- Sponsors Eli Lilly and Company
- 06 Jul 2022 Results published in the British Journal of Dermatology
- 25 Apr 2021 Primary endpoint (Percentage of Participants Achieving a 90% Improvement from Baseline in Psoriasis Area and Severity Score (PASI 90)) has been met, as per results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
- 25 Apr 2021 Primary endpoint (Percentage of Participants with a Static Physicians Global Assessment of (sPGA) (0,1) with at Least a 2-point Improvement from Baseline) has been met, as per results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.